Shiping Jiao

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

G. Hortobagyi, M. Hung, Seung-Oe Lim, 2017, Clinical Cancer Research.

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer

Jun Yao, G. Hortobagyi, L. Nie, 2017, Oncogene.

Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy

P. Sharma, Zhongqi Ge, A. Aparicio, 2019, Cell.

Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis

Fan Yang, Yongmei Yin, Chunxiao Sun, 2021, Journal of Experimental & Clinical Cancer Research.

Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: A retrospective study.

Wenjie Liu, Hailin Tang, Cheng Peng, 2015, Cancer biomarkers : section A of Disease markers.

BikDDA, a Mutant of Bik with Longer Half-Life Expression Protein, Can Be a Novel Therapeutic Gene for Triple-Negative Breast Cancer

Hailin Tang, Xiaoming Xie, Xinhua Xie, 2014, PloS one.

Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling

Meisi Yan, Beicheng Sun, Tong Liu, 2022, Journal for ImmunoTherapy of Cancer.

Single-cell immune profiling of matched disease and recovery phase blood of COVID-19 patients reveals anti-LAG3 based immune checkpoint therapy as a promising option

Beicheng Sun, S. Jiao, Xiao-Bo Yan, 2020 .